Data Sheet | January 14, 2025
NULISAseq™ CNS Disease Panel 120
Get the Resource
Download NowSapient offers the NULISAseq CNS Disease Panel 120 for the most comprehensive profiling of biomarkers of neurodegenerative disease progression and response to therapy, at the lowest limit of detection.
The CNS Disease Panel provides best-in-class sensitivity and robust, multiplexed analysis of 120+ neuro-specific and inflammatory proteins from 10 µl of plasma or CSF, including critical biomarkers such as pTau-217, GFAP, NfL, and alpha-synuclein.
As a Certified Service Provider of Alamar Biosciences NULISA™ panels and assays, Sapient brings deep expertise in Alamar’s technologies as well as the scientific prowess to effectively interrogate key neuroinflammatory pathways – including in the low-abundance portion of the proteome – supporting discovery and validation of protein biomarkers and targets associated with neurodegenerative diseases.
Download the data sheet to learn how the NULISAseq CNS Disease Panel enables:
- Broad coverage of >120 CNS disease-associated protein targets with >90% detectability in plasma
- Detection of low-abundant biomarkers with attomolar (fg/mL) sensitivity
- Measure of protein changes with up to 12 logs of dynamic range in a single sample without dilution
- Reproducibility of measures with median CVs <10%
You can also learn how NULISA panels complement our mass spectrometry-based proteomics services to cover the wide dynamic range of proteins in plasma and enable cross-validation of measures to rapidly confirm and advance biomarker findings.